A.O. 'Pia Fondazione Cardinale G. Panico'
Welcome,         Profile    Billing    Logout  
 3 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tamburini, Emiliano
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting
2
173
Europe
Cetuximab, Erbitux, Avelumab, Bavencio
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Cancer
07/25
07/25
CAPRI 2 GOIM, NCT05312398: Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Active, not recruiting
2
219
Europe
Cetuximab, Erbitux, FOLFIRI, FOLFOX regimen, FOLFOX, Irinotecan
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Adenocarcinoma
08/25
06/26
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24

Download Options